Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
Conclusions:
Approximately 10 years of agalsidase alfa treatment appeared to have beneficial effects for controlling progression and improving some symptoms of Fabry-associated cardiomyopathy.
Source: Orphanet Journal of Rare Diseases - Category: Internal Medicine Authors: Christoph KampmannAmandine PerrinMichael Beck Source Type: research
More News: Cardiology | Cardiomyopathy | Heart | Heart Failure | Internal Medicine | Rare Diseases | Women